← Back to Search
N-(2-hydroxypropyl)methacrylamide Copolymers Targeted To The Hepatocyte Galactose-receptor: Pharmacokinetics In DBA2 Mice.
L. Seymour, K. Ulbrich, S. Wedge, I. Hume, J. Strohalm, R. Duncan
Published 1991 · Medicine
Download PDFAnalyze on Scholarcy
N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymers containing doxorubicin (DOX) and galactosamine can be targeted to the hepatocyte galactose receptor for organ-specific chemotherapy of primary and metastatic liver cancer. Here we report the dose-dependent pharmacokinetics of this macromolecular conjugate. Following intravenous administration to mice most efficient liver targeting was seen at low dose (0.05 mg DOX kg-1), with receptor saturation observed using higher bolus doses. Repeated low dose bolus injections did not cause down-regulation of the galactose receptor and targeted drug delivery rates of greater than or equal to 2 micrograms DOX g-1 liver h-1 were achieved. DOX is released from such conjugates intracellularly via action of lysosomal proteinases. It was shown that isolated rat liver lysosomal enzymes (Tritosomes) can release unmodified DOX from the peptidyl side chain Gly-Phe-Leu-Gly at a rate greater than or equal to 3 micrograms DOX g-1 liver h-1 i.e. the hydrolytic capacity is greater than the observed rate of drug delivery to the liver lysosomes in vivo. Although most conjugate would be captured by normal hepatocytes following intravenous administration, it was shown that the human hepatoma cell line HepG2 retains the galactose receptor, accumulating and processing the conjugate efficiently. Potential dose limiting toxicities of such drug conjugates could include cardio- or hepatotoxicity. Administration of conjugate reduced the 15 min heart level of DOX approximately 100-fold compared with that observed for an equivalent dose of free drug. Preliminary experiments showed that plasma levels of alkaline phosphatase, alanine transaminase and asparate transaminase did not change following administration of HPMA copolymer-daunorubicin (DNR) (10 mg DNR kg-1) indicating no significant heptatoxicity.
This paper references
Receptor-mediated delivery of drugs to hepatocytes
R. Fallon (1989)
Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats.
L. Seymour (1987)
Reduced cardiotoxicity of doxorubicin by a 6‐hour infusion regimen. A prospective randomized evaluation
J. Shapira (1990)
Determina - tion of adriamycin , adriamycinol and their 7 - deoxyaglycones in human serum by high performance liquid chromatography
J. CUMMINGS (1984)
Quantitative studies of pinocytosis. II. Kinetics of protein uptake and digestion by rat yolk sac cultured in vitro
K. Williams (1975)
Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers. A potential drug delivery system.
R. Duncan (1981)
Comparative toxicity of HPMA copolymer-adriamycin conjugates and free adriamycin
Recent studies on doxorubicin and its analogues.
J. R. Brown (1984)
Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers.
P. Rejmanová (1985)
Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases.
N. Chiannilkulchai (1989)
Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues.
R. Duncan (1983)
Degradation of side chains of N-(2-hydroxypropyl) methacrylamide copolymers by lysosomal enzymes.
R. Duncan (1980)
Effect of galactose on interaction of N-(2-hydroxypropyl) methacrylamide copolymers with hepatoma cells in culture: preliminary applications to an anticancer
L. SCARLErT (1989)
The role of extra-hepatic tissues in the receptor-mediated plasma clearance of glycoproteins terminated by mannose or N-acetylglucosamine.
P. Schlesinger (1980)
Clinical trials in primary hepatocellular carcinoma: current status and future directions.
S. Nerenstone (1988)
Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats.
R. Duncan (1986)
Poly[N‐(2‐hydroxypropyl)methacrylamide]. IV. Heterogeneous polymerization
J. Strohalm (1978)
Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo
R. Duncan (1989)
Intrahepatic arterial chemotherapy with cytotoxic drug - containing microspheres
D. J. KERR (1989)
Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model.
J. Cassidy (1989)
Hepatic uptake of asialoglycoprotein is different among mammalian species due to different receptor distribution.
T. Chang (1988)
Drug delivery using vesicles targeted to the hepatic asialoglycoprotein receptor.
P. Dragsten (1987)
Human hepatic lectin. Physiochemical properties and specificity.
J. Baenziger (1980)
Turnover of the surface proteins and the receptor for serum asialoglycoproteins in primary cultures of rat hepatocytes.
R. Warren (1981)
Quantitative studies of pinocytosis. I. Kinetics of uptake of (125I)polyvinylpyrrolidone by rat yolk sac cultured in vitro
K. Williams (1975)
Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro.
B. Říhová (1989)
Pilotage des anthracyclines et hépatomes.
F. Ceulemans (1987)
COPOLYMERS OF 6-O-METHACRYLOYL-D-GALACTOSE AND N-(2-HYDROXYPROPYL)METHACRYLAMIDE: TARGETING TO LIVER AFTER INTRAVENOUS ADMINISTRATION TO RATS.
V. Chytrý (1987)
Bio - compatibility of N - ( 2 - hydroxypropyl ) methacrylamide copolymers containing adriamycin
B. RIHOVA (1989)
Endocytosis ofproteins by liver cells
Effect of galactose on interaction of N‐(2‐hydroxypropyl)methacrylamide copolymers with hepatoma cells in culture: Preliminary application to an anticancer agent, daunomycin
Kathryn B. O'Hare (1989)
Stability in plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide
J. B. LLOYD (1985)
Clinical chemistry in diagnosis and treatment
J. Zilva (1985)
The pharmacokinetics of polymer-bound adriamycin.
L. Seymour (1990)
Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.
I. Virgolini (1990)
Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.
J. Cummings (1984)
Drug Targeting in Human Cancer Chemotherapy
Y. Schneider (1984)
Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line.
A. Schwartz (1982)
Effect of molecular weight (Mw) of N-(2-hydroxypropyl) methacrylamide copolymers
J. STROHALM (1987)
Copolymers of 6o - methacryloyl - D - galactose and N - ( 2 - hydroxypropyl ) methac - rylamide copolymers : targeting to liver after intravenous administration to rats
V. CHYTRY (1987)
Endocytosis ofproteins by liver cells
T. KOOISTRA (1979)
Degradation of side-chains ofN-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases
R. Duncan (1982)
Determination of total protein.
G. L. Peterson (1983)
In vivo quantification of receptor-mediated uptake of asialoglycoproteins by rat liver.
W. Pardridge (1983)
Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies.
S. Order (1980)
Natural history of primary and secondary tumours of the liver
G. P. Ellis (1983)
Comparative toxicity of HPMA copolymer - adriamycin conjugates and free adriamycin
T. K. YEUNG (1989)
Technetium-99m galactosyl-neoglycoalbumin: preparation and preclinical studies.
D. Vera (1985)
Isolation of modified liver lysosomes.
A. Trouet (1974)
Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes†
R. Duncan (1983)
Natural history of primary and secondary tumors of the liver.
B. Cady (1983)
This paper is referenced by
DNA-intercalators — the anthracyclines
K. Mross (2006)
Structural and chemical aspects of HPMA copolymers as drug carriers.
K. Ulbrich (2010)
A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression
K. Fisher (2000)
Synthesis of novel hydrolytically degradable hydrogels for controlled drug release
K. Ulbrich (1995)
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy
Y. Zhong (2013)
Nanosized systems for efficient delivery of antitumoral and anti-inflammatory drugs
R. Pireddu (2015)
SÍNTESE DE POLÍMEROS GLICOSILADOS E APLICAÇÃO COMO COMPONENTES DE NANOPARTÍCULAS PARA VETORIZAÇÃO DE FÁRMACOS
Bruna Donida (2010)
Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.
H. Maeda (1992)
Intraperitoneal and subcutaneous retention of a soluble polymeric drug-carrier bearing galactose
L. Seymour (1991)
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.
P. Julyan (1999)
Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier.
J. H. Han (1999)
HPMA‐based Biodegradable Hydrogels Containing Different Forms of Doxorubicin Antitumor Effects and Biocompatibility a
B. Říhová (1997)
Biodegradable microspheres. 17. Lysosomal degradation of primaquine-peptide spacer arms.
R. Borissova (1995)
Prodrug Strategies in Anticancer Chemotherapy
F. Kratz (2008)
Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.
T. Lammers (2010)
Investigations of the mechanisms of antitumour activity of PKI, the first macromolecular prodrug to reach clinical trials.
Quarcoo Tn (2010)
Synthesis and biological characterisation of HPMA copolymer-mannose conjugates designed for intracellular delivery of anti-leishmanial compounds to macrophages.
Kerri-Lee. Wallom (2008)
Water Soluble Polymers for Pharmaceutical Applications
Veeran Gowda Kadajji (2011)
Polymer therapeutics designed for a combination therapy of hormone-dependent cancer.
M. Vicent (2005)
Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics
Sindisiwe Mvango (2018)
Design and synthesis of pH-responsive polymeric carriers that target uptake and enhance the intracellular delivery of oligonucleotides.
N. Murthy (2003)
Carbohydrate-based amphiphilic nano delivery systems for cancer therapy.
Kegang Liu (2016)
In vitro binding specificity of glycosylated dextrans to the asialoglycoprotein receptor of primary hepatocytes
D. Anderson (1995)
3. Polymer–Drug Conjugates
Cristina Fante and (2014)
N-(2-Hydroxypropyl) methacrylamide Copolymer
R. Duncan (2005)
Targeted nanoparticles for detecting and treating cancer
C. J. Sunderland (2006)
Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
B. Říhová (2008)
Soluble polymers for lectin-mediated drug targeting
L. Seymour (1994)
Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer.
N. K. Green (2012)
Cancer Therapy with RNAi Delivered by Non-viral Membrane/Core Nanoparticles
A. Satterlee (2014)
Macromolecular Systems for Chemotherapy and Magnetic Resonance Imaging.
S. Matthews (1996)
Galactosamine Following Intravenous Administration to Nude Mice Bearing Hepatic Human Colon Carcinoma
M. V. Pimm (1996)See more